Shiyue Li1, Guangfa Wang2, Changhui Wang3, Xinglin Gao4, Faguang Jin5, Huaping Yang6, Baohui Han7, Rui Zhou8, Chengshui Chen9, Liangan Chen10, Chunxue Bai11, Huahao Shen12, Felix J F Herth13, Nanshan Zhong14. 1. The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. 2. Peking University First Hospital, Beijing, China. 3. Shanghai Tenth People's Hospital, Shanghai, China. 4. Guangdong General Hospital, Guangzhou, China. 5. Tangdu Hospital, The Second Teaching Hospital of The Fourth Military Medical University, Xi'an, China. 6. Xiangya Hospital of Central South University, Changsha, China. 7. Shanghai Chest Hospital affiliated to Shanghai Jiaotong University, Shanghai, China. 8. The Second Xiangya Hospital of Central South University, Changsha, China. 9. The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, China. 10. The General Hospital of the Chinese People's Liberation Army (301), Beijing, China. 11. Zhongshan Hospital, Fudan University, Shanghai, China. 12. The Second Affiliated Hospital, ZheJiang University School of Medicine, Hangzhou, China. 13. Thoraxklinik and Translational Lung Research Center, University of Heidelberg, Heidelberg, Germany. 14. The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, profnzmd@gmail.com.
Abstract
BACKGROUND:Chronic obstructive pulmonary disease (COPD) has become a leading cause of morbidity and mortality in China, with tobacco smoke, air pollution, and occupational biohazards being the major risk factors. OBJECTIVES: The REACH trial is a multicenter, prospective, randomized controlled trial undertaken in China to assess the safety and effectiveness of the Spiration® Valve System (SVS) compared to standard medical care in COPD patients with severe emphysema. METHODS:Patients with severe airflow obstruction, hyperinflation, and severe dyspnea with interlobar fissure integrity were evaluated for enrollment. A total of 107 subjects were randomized in a 2: 1 allocation ratio to either the treatment group (SVS valves and medical management) or the control group (medical management alone). RESULTS: The 3-month primary endpoint showed statistically significant improvement in forced expiratory volume in 1 s in the treatment group compared to the control group (0.104 ± 0.18 vs. 0.003 ± 0.15 L, p = 0.001), with the difference being durable through 6 months. Statistically significant target lobe volume reduction was achieved at 3 months (mean change 684.4 ± 686.7 mL) and through 6 months (757.0 ± 665.3 mL). Exercise function and quality of life measures improved in the treatment group, but showed a deterioration in the control group. The serious adverse event (SAE) rate was 33% in the treatment group and 24.2% in the control group. The predominance of SAEs were acute exacerbations of COPD in both groups. There was 1 death in the control group and no deaths in the treatment group. CONCLUSION: The SVS represents a novel approach for the treatment of severe emphysema with a clinically acceptable risk-benefit profile.
RCT Entities:
BACKGROUND:Chronic obstructive pulmonary disease (COPD) has become a leading cause of morbidity and mortality in China, with tobacco smoke, air pollution, and occupational biohazards being the major risk factors. OBJECTIVES: The REACH trial is a multicenter, prospective, randomized controlled trial undertaken in China to assess the safety and effectiveness of the Spiration® Valve System (SVS) compared to standard medical care in COPDpatients with severe emphysema. METHODS:Patients with severe airflow obstruction, hyperinflation, and severe dyspnea with interlobar fissure integrity were evaluated for enrollment. A total of 107 subjects were randomized in a 2: 1 allocation ratio to either the treatment group (SVS valves and medical management) or the control group (medical management alone). RESULTS: The 3-month primary endpoint showed statistically significant improvement in forced expiratory volume in 1 s in the treatment group compared to the control group (0.104 ± 0.18 vs. 0.003 ± 0.15 L, p = 0.001), with the difference being durable through 6 months. Statistically significant target lobe volume reduction was achieved at 3 months (mean change 684.4 ± 686.7 mL) and through 6 months (757.0 ± 665.3 mL). Exercise function and quality of life measures improved in the treatment group, but showed a deterioration in the control group. The serious adverse event (SAE) rate was 33% in the treatment group and 24.2% in the control group. The predominance of SAEs were acute exacerbations of COPD in both groups. There was 1 death in the control group and no deaths in the treatment group. CONCLUSION: The SVS represents a novel approach for the treatment of severe emphysema with a clinically acceptable risk-benefit profile.
Authors: Felix J F Herth; Marc Noppen; Arschang Valipour; Sylvie Leroy; Jean-Michel Vergnon; Joachim H Ficker; Jim J Egan; Stefano Gasparini; Carlos Agusti; Debby Holmes-Higgin; Armin Ernst Journal: Eur Respir J Date: 2012-01-26 Impact factor: 16.671
Authors: Nicholas S Hopkinson; Tudor P Toma; David M Hansell; Peter Goldstraw; John Moxham; Duncan M Geddes; Michael I Polkey Journal: Am J Respir Crit Care Med Date: 2004-12-03 Impact factor: 21.405
Authors: Frank C Sciurba; Armin Ernst; Felix J F Herth; Charlie Strange; Gerard J Criner; Charles H Marquette; Kevin L Kovitz; Richard P Chiacchierini; Jonathan Goldin; Geoffrey McLennan Journal: N Engl J Med Date: 2010-09-23 Impact factor: 91.245
Authors: Gerard J Criner; Francis Cordova; Alice L Sternberg; Fernando J Martinez Journal: Am J Respir Crit Care Med Date: 2011-10-15 Impact factor: 21.405
Authors: Alfred Fishman; Fernando Martinez; Keith Naunheim; Steven Piantadosi; Robert Wise; Andrew Ries; Gail Weinmann; Douglas E Wood Journal: N Engl J Med Date: 2003-05-20 Impact factor: 91.245
Authors: Klaus F Rabe; Suzanne Hurd; Antonio Anzueto; Peter J Barnes; Sonia A Buist; Peter Calverley; Yoshinosuke Fukuchi; Christine Jenkins; Roberto Rodriguez-Roisin; Chris van Weel; Jan Zielinski Journal: Am J Respir Crit Care Med Date: 2007-05-16 Impact factor: 21.405
Authors: Karin Klooster; T David Koster; Christoph Ruwwe-Glösenkamp; Dorothea Theilig; Felix Doellinger; Jacopo Saccomanno; Huib A M Kerstjens; Dirk-Jan Slebos; Ralf-Harto Hübner Journal: Int J Chron Obstruct Pulmon Dis Date: 2020-06-09
Authors: Gerard J Criner; Antoine Delage; Kirk Voelker; D Kyle Hogarth; Adnan Majid; Michael Zgoda; Donald R Lazarus; Roberto Casal; Sadia B Benzaquen; Robert C Holladay; Adam Wellikoff; Karel Calero; Mark J Rumbak; Paul R Branca; Muhanned Abu-Hijleh; Jorge M Mallea; Ravi Kalhan; Ashutosh Sachdeva; C Matthew Kinsey; Carla R Lamb; Michael F Reed; Wissam B Abouzgheib; Phillip V Kaplan; Gregory X Marrujo; David W Johnstone; Mario G Gasparri; Arturo A Meade; Christopher A Hergott; Chakravarthy Reddy; Richard A Mularski; Amy Hajari Case; Samir S Makani; Ray W Shepherd; Benson Chen; Gregory E Holt; Simon Martel Journal: Am J Respir Crit Care Med Date: 2019-12-01 Impact factor: 21.405
Authors: Pavlina Lenga; Christoph Ruwwe-Glösenkamp; Christian Grah; Joachim Pfannschmidt; Jens Rückert; Stephan Eggeling; Sven Gläser; Bernd Schmidt; Paul Schneider; Sylke Kurz; Gunda Leschber; Andreas Gebhardt; Birgit Becke; Olaf Schega; Jakob Borchardt; Ralf-Harto Hübner Journal: ERJ Open Res Date: 2021-01-25
Authors: C F N Koegelenberg; R N van Zyl-Smit; K Dheda; B W Allwood; M J Vorster; D Plekker; D-J Slebos; K Klooster; P L Shah; F J F Herth Journal: Afr J Thorac Crit Care Med Date: 2022-06-20
Authors: Marlies van Dijk; Rick Sue; Gerard J Criner; Daniela Gompelmann; Felix J F Herth; D Kyle Hogarth; Karin Klooster; Janwillem W H Kocks; Hugo G de Oliveira; Pallav L Shah; Arschang Valipour; Dirk-Jan Slebos Journal: Respiration Date: 2021-06-01 Impact factor: 3.580